Janssen's hepatitis C drug gets FDA panel endorsement

10/25/2013 | Medscape (free registration) · PharmaTimes (U.K.)

An FDA panel endorsed the approval of Janssen's simeprevir to be used in combination with peginterferon alfa and ribavirin to treat chronic hepatitis C in treatment-naive adults with compensated liver disease. The therapy is also intended for patients who did not respond to previous interferon treatment.

View Full Article in:

Medscape (free registration) · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC